Suppr超能文献

相似文献

1
Genetic alterations of PTEN in human melanoma.
Cell Mol Life Sci. 2012 May;69(9):1475-91. doi: 10.1007/s00018-011-0878-0. Epub 2011 Nov 11.
2
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Am J Pathol. 2000 Oct;157(4):1123-8. doi: 10.1016/S0002-9440(10)64627-5.
3
BRN2 is a non-canonical melanoma tumor-suppressor.
Nat Commun. 2021 Jun 17;12(1):3707. doi: 10.1038/s41467-021-23973-5.
4
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.
Melanoma Res. 2002 Dec;12(6):565-75. doi: 10.1097/00008390-200212000-00006.
6
Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell survival and migration.
Arch Dermatol Res. 2021 Sep;313(7):583-591. doi: 10.1007/s00403-020-02139-1. Epub 2020 Sep 21.
7
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J Invest Dermatol. 2004 Feb;122(2):337-41. doi: 10.1046/j.0022-202X.2004.22243.x.
8
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Carcinogenesis. 2006 Sep;27(9):1778-86. doi: 10.1093/carcin/bgl016. Epub 2006 Mar 29.
9
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.
J Invest Dermatol. 2000 Feb;114(2):277-80. doi: 10.1046/j.1523-1747.2000.00877.x.

引用本文的文献

1
Assessment of 1863 Variants Contradicts a Role in Tumorigenesis.
Int J Mol Sci. 2025 Jun 10;26(12):5558. doi: 10.3390/ijms26125558.
2
Skin Photodamage and Melanomagenesis: A Comprehensive Review.
Cancers (Basel). 2025 May 26;17(11):1784. doi: 10.3390/cancers17111784.
3
Diagnostics and Therapy for Malignant Tumors.
Biomedicines. 2024 Nov 21;12(12):2659. doi: 10.3390/biomedicines12122659.
4
Prognostic Biomarkers in Evolving Melanoma Immunotherapy.
Am J Clin Dermatol. 2025 Mar;26(2):213-223. doi: 10.1007/s40257-024-00910-y. Epub 2024 Dec 21.
5
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.
Cancer Drug Resist. 2024 Oct 31;7:42. doi: 10.20517/cdr.2024.54. eCollection 2024.
6
Molecular Susceptibility and Treatment Challenges in Melanoma.
Cells. 2024 Aug 20;13(16):1383. doi: 10.3390/cells13161383.
8
A Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer.
Cancer Control. 2024 Jan-Dec;31:10732748241238047. doi: 10.1177/10732748241238047.
9
Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum.
Cancers (Basel). 2023 Dec 14;15(24):5834. doi: 10.3390/cancers15245834.

本文引用的文献

1
Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.
Br J Dermatol. 2011 Dec;165(6):1219-22. doi: 10.1111/j.1365-2133.2011.10551.x. Epub 2011 Nov 2.
3
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene. 2012 Jan 26;31(4):446-57. doi: 10.1038/onc.2011.250. Epub 2011 Jul 4.
4
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
5
Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene.
Cancer Genet. 2011 Apr;204(4):224-5. doi: 10.1016/j.cancergen.2010.12.011.
6
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11.
7
10
Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.
Cancer Biol Ther. 2010 Dec 1;10(11):1194-200. doi: 10.4161/cbt.10.11.13814.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验